Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
beta_blocker_toxicity [2024/11/26 01:40] – jkohts | beta_blocker_toxicity [2025/01/07 19:45] (current) – jkohts | ||
---|---|---|---|
Line 10: | Line 10: | ||
===== - Classification ===== | ===== - Classification ===== | ||
- | There are a number of ways to classify β-blockers. A simple functional classification is described in the table below [(31178382> | + | There are a number of ways to classify β-blockers. A simple functional classification |
<WRAP group>< | <WRAP group>< | ||
Line 24: | Line 24: | ||
==== - β-adrenergic antagonism ==== | ==== - β-adrenergic antagonism ==== | ||
- | Antagonism of β-receptors | + | Excess competitive inhibition at β-adrenergic |
- | **β1 adrenergic antagonism**\\ | + | **β1-adrenergic antagonism**\\ |
+ | β1-receptors are found primarily in cardiac tissue, and when stimulated results in increased chronotropy, | ||
+ | **β2-adrenergic antagonism**\\ | ||
+ | β2-receptors are found in peripheral smooth muscle vasculature, | ||
- | **β2 adrenergic antagonism**\\ | + | β-blockers may also cause hypoglycemia by inhibition of hepatic glycogenolysis and pancreatic glucagon release. Counter-regulation by adrenaline is also diminished by β-blockade, |
- | Other effects In addition to their cardiac effects, beta blocking drugs may also cause hypoglycaemia (by inhibiting glycogenolysis) and /or bronchospasm (in susceptible individuals.) | ||
- | Propranolol and sotalol have the highest relative toxicity due to other pharmacological properties of these drugs: sodium channel blockade (propranolol) and potassium channel blockade (sotalol). | ||
==== - Features of β-blockers ==== | ==== - Features of β-blockers ==== | ||
- | < | ||
- | Note that this section has bullets with exposition, and then subheadings with exposition. Please can you compare and we can decide how to move forward with similar situations. | ||
- | Options: | ||
- | - Bullet points only for headers + description below with subheadings (like the original https:// | ||
- | - Bullet points for headers + description in bullet points | ||
- | - Subheadings with description, | ||
- | </ | ||
- | |||
Individual drugs in this class differ based on their unique pharmacological properties, which include: | Individual drugs in this class differ based on their unique pharmacological properties, which include: | ||
- | | + | * Cardioselectivity |
- | * While β1-selectivity can influence adverse effects in therapeutic use, it becomes less relevant in overdose situations because selectivity is lost at high drug concentrations. | + | * Intrinsic sympathomimetic activity |
- | | + | * Class I antiarrhythmic effects |
- | * Some β-blockers have ISA due to partial β agonism and may result in tachycardia and hypertension. This partial agonist effect rarely leads to significant problems and probably protects to some extent from the more serious class I and III antiarrhythmic effects. | + | * Class III antiarrhythmic effects |
- | * Drugs with ISA include acebutolol, pindolol, labetalol, and celiprolol. | + | * Vasodilatory activity |
- | | + | * Lipid solubility |
- | * The membrane-stabilizing activity of some β-blockers is due to the inhibition of fast Na+ channels (class I anti-arrhythmic activity). These effects usually only occur at high drug concentrations. | + | * Renal/ |
- | * Propranolol has the most membrane-stabilizing activity of the β-blockers and can result in impaired AV conduction, widened QRS interval, ventricular tachyarrhythmias, | + | |
- | | + | |
- | * Some β-blockers block the delayed rectifier outward K+ channel which is responsible for cell repolarization. This prolongs the action potential duration and prolongs the QT interval. | + | |
- | * Examples of these β-blockers include sotalol and acebutolol. | + | |
- | | + | |
- | * The vasodilatory activity of certain β-blockers can theoretically enhance the hypotensive effects in cases of β-blocker overdose. | + | |
- | | + | |
- | * Only lipid soluble drugs will lead to direct CNS effects as they are able to penetrate the blood brain barrier, though CNS symptoms may occur secondary to cardiac effects and decreased cerebral perfusion. | + | |
- | * Lipid solubility alone will not lead to CNS effects and they may relate to Na+ channel blocking effects as they are particularly common with propranolol. | + | |
- | | + | |
- | * This is occasionally important in therapeutics but is largely irrelevant to overdose. | + | |
- | + | ||
**Cardioselectivity (β1-selectivity)**\\ | **Cardioselectivity (β1-selectivity)**\\ | ||
Line 85: | Line 65: | ||
**Renal/ | **Renal/ | ||
- | This is occasionally important in therapeutics but is largely irrelevant | + | This is occasionally important in therapeutics but is largely irrelevant |
Line 141: | Line 121: | ||
==== - Respiratory effects ==== | ==== - Respiratory effects ==== | ||
**Bronchospasm**\\ | **Bronchospasm**\\ | ||
- | β-blocker overdose can result in bronchospasm as a result of β2 antagonism, particularly in individuals with underlying reactive airway disease. | + | β-blocker overdose can result in bronchospasm as a result of β2 antagonism, particularly in individuals with underlying reactive airway disease. |
==== - Metabolic effects ==== | ==== - Metabolic effects ==== | ||
Line 150: | Line 130: | ||
< | < | ||
- | Need to check this - never seen this elsewhere: | + | Two problems here. |
+ | (1) The above are contradictory. | ||
+ | |||
+ | (2) Need to check this - never seen this elsewhere: | ||
There are some reports of patients responding to glucose with “normal” blood glucose measurements. Therefore, it is worth giving a bolus of 50% glucose to any patient with CNS effects. | There are some reports of patients responding to glucose with “normal” blood glucose measurements. Therefore, it is worth giving a bolus of 50% glucose to any patient with CNS effects. | ||
</ | </ | ||
Line 186: | Line 169: | ||
**Propranolol**\\ | **Propranolol**\\ | ||
- | Propranolol is the only beta-blocker that frequently causes seizures. In one series, of those who ingested more than 2 g of propranolol, | + | Propranolol is the only beta-blocker that frequently causes seizures |
- | Seizures are a common and serious complication of poisoning with lipophilic beta-blockers such as propranolol and may precipitate cardiac complications.. | + | |
- | Compared with the other β-adrenergic antagonists, | + | |
**Sotalol**\\ | **Sotalol**\\ | ||
- | Sotalol may frequently cause significant QT prolongation and torsade de pointes (occasionally reported with propranolol) as well as the usual manifestations of beta blockade. Other factors relate to: | + | Sotalol may frequently cause significant QT prolongation and torsade de pointes (occasionally reported with propranolol) as well as the usual manifestations of beta-blockade. Other factors relate to its intrinsic |
- | + | ||
- | < | + | |
- | Intrinsic | + | |
- | Lipid solubility (CNS effects) | + | |
- | + | ||
- | </ | + | |
Line 204: | Line 179: | ||
==== - Supportive ==== | ==== - Supportive ==== | ||
- | IV access | + | IV access |
+ | |||
+ | < | ||
+ | Again the empirical glucose administration needs to be checked. | ||
+ | </ | ||
==== - Decontamination ==== | ==== - Decontamination ==== | ||
- | Syrup of ipecac should not be used to decontaminate beta-blocker poisonings under any circumstances. | + | **Gastric lavage** should be considered in large ingestions of propranolol or sotalol if patients present within one hour of ingestion. Atropine should be given prior to lavage and in any patient who is vomiting. |
+ | |||
+ | **Oral activated charcoal** should be given to all patients ingesting any overdose of a β-blocking drug who present within 2 hours. | ||
+ | |||
+ | **Whole bowel irrigation** may be considered in patients who have ingested sustained-release preparations. | ||
+ | |||
+ | **Induction of emesis** (e.g. with syrup of ipecac) is __contraindicated__ in β-blocker toxicity due to risk of airway compromise (from aspiration and reduced consciousness) and vagal stimulation which may worsen bradycardia. | ||
==== - Enhanced elimination ==== | ==== - Enhanced elimination ==== | ||
+ | The drugs that are water soluble are predominantly renally cleared, namely sotalol and atenolol. Among these drugs, sotalol has significant ' | ||
- | The drugs that are water soluble are predominantly renally cleared. Among these drugs, only sotalol has significant “antiarrhythmic” effects and frequently causes life threatening | + | Extracorporeal treatment with renal replacement therapies (intemittent hemodialysis preferred) can be considered in patients who have all of the following [(34112223> |
+ | * Sotalol or atenolol toxicity | ||
+ | * Significant renal impairment | ||
+ | *__Refractory__ cardiotoxic effects (bradycardia, hypotension, | ||
+ | |||
+ | < | ||
+ | I have removed the argument where sotalol | ||
+ | </ | ||
==== - Antidote ==== | ==== - Antidote ==== | ||
- | There are a number of drugs that will antagonize some of the cardiac effects of beta-blockers. All these treatments may be used simultaneously, if this is required | + | There are a number of drugs that will antagonize some of the cardiac effects of beta-blockers. All these treatments may be used simultaneously if required. |
+ | * Atropine | ||
+ | * Glucagon | ||
+ | * Isoprenaline | ||
+ | * Dextrose & Insulin | ||
- | < | + | **Atropine**\\ |
- | | + | This should be tried in all patients with bradycardia. It should be given prior to intubation, lavage, or any other procedure that might increase vagal tone and in patients who are nauseated or vomiting. |
- | | + | |
- | Isoprenaline | + | |
- | Dextrose & Insulin | + | |
- | </code> | + | **Glucagon**\\ |
+ | IV glucagon had been used as antidote for beta-blocker poisoning in the past but its use has been largely superseded by HIET. Glucagon increases intracellular cAMP and activates myosin kinase independent of β-receptors. | ||
+ | \\ | ||
+ | * 💊 **Glucagon** IV 5-10 mg as a bolus, then an IV infusion titrated against heart rate and blood pressure (starting at 5-10 mg/hour, or the ' | ||
- | Atropine | + | **Isoprenaline** |
+ | Isoprenaline is a non-selective competitive β-agonist. Doses should | ||
- | **Glucagon** \\ Glucagon had been used as antidote for beta-blocker poisoning in the past but its use has been largely superseded by insulin dextrose. The rationale for its use is that it increases cyclic AMP and activates myosin kinase independent of beta-receptors. The dose is 5 - 10 mg IV as a bolus and then an infusion titrated against heart rate and blood pressure (starting at 5 - 10 mg/hour). | ||
- | **Isoprenaline** This is a non-selective competitive beta agonist. Doses should | + | **HIET**\\ |
+ | Patients who require inotropics support should be commenced on Dextrose & Insulin. | ||
- | Patients who require inotropics support should be commenced on Dextrose & Insulin. | + | < |
+ | This section has been reworked 08/01. Goldfrank' | ||
+ | Do we want to include those in? | ||
+ | Also, in what order should we include them? | ||
+ | </ | ||
- | This should be implemented in patients not responding to isoprenaline. | ||
==== - Treatment of specific complications ==== | ==== - Treatment of specific complications ==== | ||
- | Seizures Glucose should be given regardless of a normal blood sugar. Otherwise, they should be treated conventionally with benzodiazepines(eg diazepam). If seizures are refractory-use phenobarbitone. | + | **Seizures**\\ |
+ | Glucose should be given regardless of a normal blood sugar. Otherwise, they should be treated conventionally with benzodiazepines (eg diazepam). If seizures are refractory, use phenobarbitone. | ||
+ | < | ||
- | Arrhythmias Ventricular tachycardia (torsades de pointes) may occur with sotalol or occasionally propranolol. Conventional treatment is with magnesium, isoprenaline, | + | **Arrhythmias**\\ |
+ | Ventricular tachycardia (polymorphic VT, torsades de pointes) may occur with sotalol or occasionally propranolol. Conventional treatment is with magnesium, isoprenaline, | ||
+ | < | ||
==== - Observation/ | ==== - Observation/ | ||
===== - Prognosis ===== | ===== - Prognosis ===== | ||
- | + | Occasional late complications/ | |
- | Occasional late complications/ | + | |
===== - References ===== | ===== - References ===== |